47 results on '"Castillo, C"'
Search Results
2. Natural history of the remnant duct after whipple for IPMN: results from an international consortium
3. The Revised R Status Is an Independent Predictor of Postresection Survival in Pancreatic Cancer after Neoadjuvant Treatment
4. Prediction Model for Severe Morbidity and Diabetes Type III after Central Pancreatectomy: Patient Selection in an International Retrospective Multicenter Study
5. Textbook Outcomes in Patients with Pancreatic Ductal Adenocarcinoma: A US-German Cross-validation International Study
6. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size and Age Identify Targets for Discontinuation
7. Outcomes of Perioperative Therapy Concepts in Stage IA-III Pancreatic Cancer – A Cross-Validation of National Cancer Database (NCDB) and German Cancer Registry of the Working Group of German Cancer Centers (WGCC/ADT)
8. Number of Worrisome Features Is Associated with Increasing Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)
9. ABO Blood Group and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasms
10. Non-Alcoholic Fatty Liver Disease (NALFD): An Underappreciated Consequence of Pancreatic Resection
11. Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections
12. Can R Status after Resection Be Predicted "A Priori" in Pancreatic Ductal Adenocarcinoma? A Proposal of Novel Simplified Radiological Criteria
13. Surgical Oncology’s Overlooked Population: A Prospective, Multi-institutional Assessment of Family and Unpaid Caregivers’ Burden when Caring for Patients with Pancreatic Cancer
14. Development of a Microfluidic Cyst Fluid Assay to Identify Pancreatic Cystic Neoplasms that Require Surgical Resection
15. An Unusual Entity Mimicking Hepatocellular Carcinoma
16. The Impact of Treatment at Minority-serving Hospitals on Outcomes for Pancreatic Cancer
17. Pancreas Transplantation with Duodeno-Duodenal Anastomosis: A Single-Center Experience
18. Perioperative Therapy in Stage IA-III Pancreatic Cancer – A Cross-validation of the National Cancer Database and the German Cancer Registry
19. Evolving trends in pancreatic cystic tumors: a 3-decade single-center experience with 1290 resections
20. Preoperative inflammatory markers do not predict prognosis for pancreatic ductal adenocarcinoma following neoadjuvant therapy
21. The impact of treatment at minority-serving hospitals on outcomes for pancreatic cancer
22. A novel microfluidic-based assay to determine high-risk pancreatic cysts for surgery utilizing pancreatic cyst fluid: an international multicenter study
23. Impact of radiological borderline resectability features on R status after neoadjuvant therapy versus upfront surgery
24. Surgical oncology's overlooked population: a prospective, multi-institutional assessment of family and unpaid caregivers' burden when caring for patients with pancreatic cancer
25. Surgery alone for resectable pancreatic ductal adenocarcinoma: should we operate if multimodal treatment is off the table?
26. A single-center experience with non-metastatic gallbladder cancer
27. Racial minorities with distal pancreatic adenocarcinoma treated at the same facilities are less likely to undergo a minimally invasive resection
28. National landscape of the treatment of early-stage pancreatic cancer
29. Serum CA 19-9 and risk of high-grade dysplasia/invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: an overlooked high-risk feature?
30. Tumor size reduction and serum CA 19-9 kinetics as metrics of resectability and response following neoadjuvant folfirinox in patients with pancreatic ductal adenocarcinoma
31. Main pancreatic duct to parenchymal thickness ratio and degree of atrophy are associated with overall survival in primarily resected pancreatic cancer
32. Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm - Associated PDAC: a Multi-Institutional Analysis
33. Facility type is associated with margin status and overall survival following minimally invasive resection for pancreatic ductal adenocarcinoma
34. Pancreatic fistula in the Era of neoadjuvant chemotherapy is an uncommon complication but may have major impact on long-term survival
35. Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?
36. Intraoperative radiation therapy (IORT) for borderline resectable and locally advance pancreatic cancer (BR/LA PDAC) in the era of modern neoadjuvant treatment: short- and long-term outcomes
37. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease
38. Neoadjuvant therapy does not alter pattern of progression in pancreatic adenocarcinoma
39. Surgical management of main duct IPMN and mixed type IPMN: an international survey and case-vignette study among experts
40. Staging laparoscopy not only saves patients an incision, but may also help them live longer
41. Comparison of hospital system characteristics at high-volume and low-volume hospitals for pancreatectomy
42. Does size matter? Reappraisal of tumour dimension as a predictor of outcome in resectable pancreatic cancer beyond the TNM
43. Predictors of postoperative outcome after distal pancreatectomy: the answer from two high-volume institutions
44. 3. HPB Surgery at Massachusetts General Hospital, Boston, USA
45. Experience in distal pancreatectomy and pancreatoduodenectomy in Clínica Alemana de Santiago.
46. Smoking impairs the effect of neoadjuvant FOLFIRINOX on Postresection survival in pancreatic cancer.
47. Natural history of the remnant pancreatic duct after pancreatoduodenectomy for non-invasive intraductal papillary mucinous neoplasm: long-term results from an international consortium.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.